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Extrapyramidal symptoms (EPS) such as antipsychotic-
induced parkinsonism (AIP) and tardive dyskinesia (TD)
are the most prominent adverse effects of first generation
(or typical) antipsychotics (FGAs). Most clinicians would
agree that concerns regarding EPS are the most important
factor limiting prescription of FGAs. As a consequence,
and not because of greater efficacy, second generation (or
atypical) antipsychotics (SGAs) are rapidly becoming the
first line treatment for schizophrenia and other psychotic
states. The extensive use of SGAs has uncovered serious
adverse effects of these agents. Prominent among these are
weight gain, which may be extensive and widespread,
hyperlipidemia and diabetes. Although EPS are common
among patients administered FGAs and metabolic syn-
drome is frequent in patients who receive SGAs, a substan-
tial proportion do not develop these adverse effects.
Genetic factors may contribute substantially to this varia-
ble, inter-individual susceptibility. Identification of the
specific genes involved could open the way to the applica-
tion of a personalized medicine approach to the prescrip-
tion of antipsychotic drugs. The most likely model is
multifactorial and polygenic and several different genes
are likely to be involved. Extensive research is under way
to identify these genes and develop valid and clinically
applicable predictive models. Associations with meta-ana-
lytic support include the role of variants in the dopamine
D3 receptor gene (DRD3) and the 5-HT2A receptor gene
(HTR2A) in susceptibility to TD. More recent findings
from of our group include the potential role of the regula-
tor of G protein signaling 2 gene (RGS2) in susceptibility
to AIP. In parallel, a search is under way for genes that
confer susceptibility to weight gain and metabolic syn-
drome in patient treated with SGAs. Our group and others
have focused on genes that influence lipid metabolism.
The results of whole genome analyses can be expected to
further advance the field. Considering that genetic factors
may also influence therapeutic effects, it is clear that per-
sonalized medicine in the field of antipsychotic treatment
will not involve a single genetic test but a multivariate tap-
estry of genetic and environmental factors that will need
to be taken into consideration in the context of a predic-
tive algorithm. Development of this algorithm is less chal-
lenging at the technological and computational level than
the implementation of urgently-needed, appropriately
designed clinical trials to identify the genes involved.
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